Comparable stake leader
Vivo Opportunity Fund Holdings, L.P.
SEC ownership of IMMUNIC, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001280776.
Disclosed value leader
Vivo Opportunity Fund Holdings, L.P.
Comparable rows
50/50
Latest evidence
29 Apr 2026
- Public ticker
- IMUX on Nasdaq
- Parsed ownership sources
- 13D/G, 13F, and 3/4/5
- Largest SEC-reported holder
- Vivo Opportunity Fund Holdings, L.P.
- Latest 13D/G holder
- Vivo Opportunity Fund Holdings, L.P.
- Latest parsed ownership date
- 29 Apr 2026
- Issuer CIK
- 0001280776
- Issuer location
- New York, United States
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of IMMUNIC, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Vivo Opportunity Fund Hol...
Disclosed value leader
Vivo Opportunity Fund Hol...
Comparable rows
50/50
Latest evidence
29 Apr 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
13D/G row: Vivo Opportunity Fund Holdings, L.P.
Showing 1-8 of 50 holder rows.
Quick read
Vivo Opportunity Fund Holdings, L.P. leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Vivo Opportunity Fund Holdings, L.P.'s linked filing trail.
Comparable ownership
Top 5
Vivo Opportunity Fund Holdings, L.P.
10%
Adage Capital Management, L.P.
10%
JANUS HENDERSON GROUP PLC
10%
BIOTECHNOLOGY VALUE FUND L P
10%
Avidity Partners Management LP
9.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
10%
|
$17,767,413
29,126,906 shares
|
$0 | 17 Feb 2026 |
| Adage Capital Management, L.P. |
13D/G
|
10%
|
$8,697,850
10,479,337 shares
|
+$7,537,012 | 30 Jun 2025 |
| JANUS HENDERSON GROUP PLC |
13D/G
|
10%
|
$8,531,675
12,016,444 shares
|
+$6,622,427 | 28 Nov 2025 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
|
$8,314,667
13,630,601 shares
|
+$2,345,708 | 12 Feb 2026 |
| Avidity Partners Management LP |
13D/G
13F
Company
|
9.9%
|
$15,493,835
13,958,410 shares
|
+$10,277,489 | 17 Feb 2026 |
| Commodore Capital LP |
13D/G
|
9.9%
|
$8,143,574
13,350,121 shares
|
$0 | 17 Feb 2026 |
| Trails Edge Capital Partners, LP |
13D/G
|
8.7%
|
$6,986,940
11,454,000 shares
|
$0 | 17 Feb 2026 |
| Deep Track Capital, LP |
13D/G
|
8.7%
|
$9,964,980
11,454,000 shares
|
$0 | 17 Feb 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$16,694.
Buys
$16,694
Insiders: 1
Sells
$0
Insiders: 0
Net
+$16,694
Shares: +20,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 20,000
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 20,000 | 0 | $16,694 | $0 | +$16,694 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to IMMUNIC, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Daniel Vitt
Net 12M change
+$16,694
Latest report
01 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Daniel Vitt | CEO and Director, Director | $352,548 | Mixed | 16 Jul 2025 | ||
| BVF PARTNERS L P/IL | Director, Other* | $260,853 | Mixed | 17 Feb 2026 | ||
| Richard A. Rudick | Director | $161,055 | Filing P/S | 05 Jun 2025 | ||
| Joerg Neermann | Director | $152,000 | Filing P/S | 05 Jun 2025 | ||
| Glenn Whaley | Chief Financial Officer | $68,079 | Filing P/S | 16 Jul 2025 | ||
| Duane Nash | Executive Chairman, Director | $30,075 | +$16,694 | +125% | Filing P/S | 16 Jul 2025 |
| Jason Tardio | President and COO | $9,884 | Filing P/S | 16 Jul 2025 | ||
| Vincent Ossipow | Director | Mixed | 15 Jun 2022 | |||
| R. Thorvald Nagel | Director | Mixed | 17 Feb 2026 | |||
| Jon Congleton | Director | Mixed | 27 Mar 2026 | |||
| Michael A. Panzara | Chief Medical Officer | Mixed | 24 Apr 2026 | |||
| Michael W. Bonney | Director | Mixed | 16 May 2026 | |||
| Erik Lundgren | Chief Executive Officer | Mixed | 01 Jun 2026 | |||
| Simona Skerjanec | Director | Mixed | 05 Jun 2025 | |||
| Andreas Muehler | Chief Medical Officer | Mixed | 16 Jul 2025 | |||
| Monika Maria Toernsen | Director | Mixed | 05 Jun 2025 | |||
| Jan van den Bossche | Director | Mixed | 15 Jun 2022 | |||
| Barclay A. Phillips | Director | Mixed | 05 Jun 2025 | |||
| Tamar D. Howson | Director | Mixed | 05 Jun 2025 |
Recent insider transactions for IMMUNIC, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Erik Lundgren | IMUX | Stock Option | Award | 1,000,000 | 1,000,000 | 22 May 2026 | Direct | |||
| Michael A. Panzara | IMUX | Stock Option | Award | 300,000 | 300,000 | 24 Apr 2026 | Direct | |||
| Glenn Whaley | IMUX | Stock Appreciation Right | Award | 1,960,000 | 560,000 | 16 Jul 2025 | Direct | |||
| Duane Nash | IMUX | Stock Appreciation Right | Award | 2,205,000 | 630,000 | 16 Jul 2025 | Direct | |||
| Daniel Vitt | IMUX | Stock Appreciation Right | Award | 6,020,000 | 1,720,000 | 16 Jul 2025 | Direct | |||
| Andreas Muehler | IMUX | Stock Appreciation Right | Award | 2,310,000 | 660,000 | 16 Jul 2025 | Direct | |||
| Jason Tardio | IMUX | Stock Appreciation Right | Award | 2,310,000 | 660,000 | 16 Jul 2025 | Direct | |||
| Duane Nash | IMUX | Common Stock | Purchase | 124.8% | $16,694 | $0.8347 | 20,000 | 36,032 | 13 Jun 2025 | Direct |
* marks a reported price that did not pass the local price check.